Clinical Trials
798 trialsNCT07551544 2026-05-19
ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer
ImmunityBio, Inc.
Phase 3 Withdrawn
NCT02943642 2026-05-18
Resimmune®
Virogen Biotechnology Inc.
Phase 2 Withdrawn
NCT03554707 2026-05-08
SGT-53 in Children With Recurrent or Progressive CNS Malignancies
SynerGene Therapeutics, Inc.
Phase EARLY_PHASE1 Withdrawn
NCT07093086 2026-05-06
Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1 Withdrawn
NCT07453446 2026-05-06
Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1 Withdrawn
NCT06765902 2026-05-05
Immunotherapy Before and After Surgery
ImmunityBio, Inc.
Phase 2 Withdrawn
NCT06765954 2026-05-05
Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.
ImmunityBio, Inc.
Phase 2 Withdrawn
NCT06145802 2026-04-29
Clinical Study of Autologous Tumor Infiltrating Lymphocyte Injection (GT316) in the Treatment of Advanced Solid Tumors (Gynecological Tumors)
Grit Biotechnology
Phase NA Withdrawn
NCT07282548 2026-04-29
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies
Ipsen
Withdrawn
NCT06434103 2026-04-08
Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Withdrawn
NCT07511972 2026-04-06
Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NGM Biopharmaceuticals, Inc
Phase 2 Withdrawn
NCT07060365 2026-04-03
A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer
AstraZeneca
Phase 1/2 Withdrawn
NCT02143804 2026-04-02
exBOND
CG Oncology, Inc.
Phase 2 Withdrawn
NCT05188573 2026-03-27
EpiDetect Study: Clinical Validation of a Pancreatic Cancer Detection Test in New-Onset Diabetes Patients
ClearNote Health
Phase NA Withdrawn
NCT05982522 2026-03-27
IN10018 Combination Therapy in Previously-treated Solid Tumors
InxMed (Shanghai) Co., Ltd.
Phase 1/2 Withdrawn
NCT06313996 2026-03-18
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Withdrawn
NCT05909527 2026-03-17
A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma
Guangzhou Bio-gene Technology Co., Ltd
Phase 1/2 Withdrawn
NCT07313891 2026-03-17
BOOST
Relmada Therapeutics, Inc.
Phase 3 Withdrawn
NCT07342517 2026-03-17
RESCUE
Relmada Therapeutics, Inc.
Phase 3 Withdrawn
NCT07211204 2026-03-03
Comparison Of Cytology And Molecular Screening For Detecting Cervical Reactive Cellular Changes In General Population
Timser SAPI de CV
Phase NA Withdrawn
NCT05296135 2026-02-27
PREDAPT-HNSCC2
Cofactor Genomics, Inc.
Withdrawn
NCT05170828 2026-02-24
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Ossium Health, Inc.
Phase 1 Withdrawn
NCT05566223 2026-02-23
CheckCell-2
Intima Bioscience, Inc.
Phase 1/2 Withdrawn
NCT06829199 2026-02-19
MK-5890-003
Merck Sharp & Dohme LLC
Phase 2 Withdrawn
NCT05312372 2026-02-17
S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC
Servier
Phase 1/2 Withdrawn
NCT07323576 2026-02-09
INAVO-CRC
Hoffmann-La Roche
Phase 2 Withdrawn
NCT05488626 2026-02-05
ARTIA-Lung
Varian, a Siemens Healthineers Company
Phase NA Withdrawn
NCT06068881 2026-01-30
Mandolin
Ipsen
Phase 2 Withdrawn
NCT06545617 2026-01-07
A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer
Bio-Thera Solutions
Phase 1/2 Withdrawn
NCT06650839 2026-01-07
POC for the Treatment of Subjects With Moderate AS Using Valvosoft® Non-Invasive Ultrasound Therapy
Cardiawave SA
Phase NA Withdrawn
NCT06881823 2025-12-29
NeoPSMA
Novartis
Phase 1/2 Withdrawn
NCT06646016 2025-12-26
EPIC
Therakos LLC
Phase 2 Withdrawn
NCT07084909 2025-12-10
HARRIER
Lantheus Medical Imaging
Phase 2/3 Withdrawn
NCT04398680 2025-12-04
DREAMM 13
GlaxoSmithKline
Phase 1 Withdrawn
NCT07150767 2025-12-02
A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Phase 1 Withdrawn
NCT07076680 2025-11-28
A Real-World Study in Patients With HR+/HER2- Advanced Breast Cancer
SciClone Pharmaceuticals
Withdrawn
NCT07026916 2025-11-17
A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer
Genfleet Therapeutics (Shanghai) Inc.
Phase 2 Withdrawn
NCT05634954 2025-10-23
Study to Evaluate Safety and Dosimetry of [18F]GEH121224 in Patients With Locally Advanced or Metastatic Breast Cancer
GE Healthcare
Phase 1 Withdrawn
NCT06557278 2025-10-21
COMUNITY
Mirror Biologics, Inc.
Phase 2 Withdrawn
NCT06884254 2025-10-14
EGC102
EirGenix, Inc.
Phase 3 Withdrawn
NCT04607772 2025-10-03
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn
NCT02151123 2025-09-26
Metabiomics Colon Cancer Clinical Research Study
Metabiomics Corp
Withdrawn
NCT06058728 2025-09-17
Pink Orchid
AbbVie
Withdrawn
NCT05263739 2025-09-12
A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies
Shanghai Escugen Biotechnology Co., Ltd
Phase 1 Withdrawn
NCT04580667 2025-08-28
Determination of Assay Cut-Off for the RadTox Test in Prostate Cancer Patients to Predict GI Radiation Toxicity
DiaCarta, Inc.
Withdrawn
NCT06555263 2025-08-22
Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer
Sutro Biopharma, Inc.
Phase 2 Withdrawn
NCT06005649 2025-08-08
Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Juventas Cell Therapy Ltd.
Phase 1/2 Withdrawn
NCT06009107 2025-08-08
B-ALL
Juventas Cell Therapy Ltd.
Phase 1/2 Withdrawn
NCT07008248 2025-08-08
Real-World Clinical Study for Malignant Tumor-Induced Cachexia
Changchun GeneScience Pharmaceutical Co., Ltd.
Withdrawn
NCT06254742 2025-08-07
A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Withdrawn